Immunoadsorption Therapy for Patients with Dilated Cardiomyopathy and Heart Failure

Uichi Ikeda1*, Hiroki Kasai1, Atsushi Izawa1, Jun Koyama1, Yoshikazu Yazaki1, Masafumi Takahashi1, Makoto Higuchi2, Chang-Sung Koh3 and Keiji Yamamoto4

Departments of 1Cardiovascular Medicine, 2Nephrology, and 3Biomedical Laboratory Sciences, Shinshu University Graduate School of Medicine, Nagano, Japan, 4Division of Cardiovascular Medicine, Jichi Medical University, Tochigi, Japan

Abstract: Several autoantibodies directed against cardiac cellular proteins including G-protein-linked receptors, contractile proteins and mitochondrial proteins, have been identified in patients with dilated cardiomyopathy (DCM). Among these autoantibodies, anti-β1-adrenoreceptor (AR) antibodies have long been discussed in terms of their pathogenetic role in DCM. Anti-β1-AR antibody-positive patients with DCM showed significant deterioration of NYHA functional class as well as reduced cardiac function compared to those in autoantibody-negative patients. Various studies with a limited number of patients indicate that the use of immunoabsorption to eliminate immunoglobulin G (IgG) significantly improves cardiac performance and clinical status in heart failure patients. Since removal of autoantibodies of the IgG3 subclass induces hemodynamic improvement and an increase in the left ventricular ejection fraction, antibodies belonging to IgG3 such as anti-β1-AR antibodies might play an important role in reducing cardiac function in patients with DCM. According to a recent report, however, the effect of hemodynamic improvement by immunoabsorption therapy was similar among patients who were positive and negative for anti-β1-AR antibodies, indicating that the beneficial effects of immunoabsorption might be not directly associated with the selective elimination of the β1-AR autoantibodies. Immunoabsorption therapy is a new therapeutic option for patients with DCM and heart failure, but further investigations are required to elucidate the specific antigens of cardiac autoantibodies responsible for the hemodynamic effects.

Key Words: Cardiomyopathy, adrenoreceptor, autoantibody, immunoabsorption, heart failure.

INTRODUCTION

Dilated cardiomyopathy (DCM) is a progressive myocardial disease characterized by contractile dysfunction and ventricular dilatation. DCM is not a rare cause of congestive heart failure and the leading reason for heart transplantation worldwide [1]. Although many different pathogenetic mechanisms and therapeutic treatments have been discussed, the ultimate answers to these questions are still lacking.

AUTOANTIBODIES IN DCM PATIENTS

A variety of experimental studies suggest that alterations of the immune system might be involved in the pathogenesis of DCM [2]. A number of antibodies against various cardiac proteins have been identified in DCM, which can be divided into sarcomembranous proteins (e.g. myosin, actin, troponin and tropomyosin), mitochondrial enzymes (e.g. the ADP-ATP carrier, nicotinamide adenine dinucleotide dehydrogenase, ubiquinol-cytochrome-c reductase, lipoamide dehydrogenase and pyruvate dehydrogenase), heat-shock proteins (e.g. hsp70, hsp60 and hsc70) and surface receptors (e.g. β1-adrenoreceptors (AR) and muscarinic receptors [3-8]). Among these, the pathogenetic role of autoantibodies against β1-AR has been well investigated in experimental models [9-11] and human DCM [12-14]. The β1-AR is a 7-transmembranare G-protein-coupled receptor abundantly expressed on cardiomyocytes.

*Address correspondence to this author at the Department of Cardiovascular Medicine, Shinshu University Graduate School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano 390-8621, Japan; Tel: 81-263-37-3191; Fax: 81-263-3795; E-mail uikeda@shinshu-u.ac.jp

Catecholamine binding to the β1-AR transmits an intracellular signal through a cAMP-dependent protein kinase A pathway that drives functional alterations in cardiomyocyte contractility.

Previously, Wallukat and his colleagues observed the immunoglobulin G (IgG) fraction in sera from DCM patients could induce a positive chronotropic effect on neonatal rat cardiac myocytes [15]. That effect was inhibited by the β1-blocking agent bisoprolol. It has also been reported that up to 33% of patients with DCM produce detectable circulating autoantibodies directed against epitope regions of the β1-AR [16], which bind to the second extracellular loop of β1-AR and cause a sustained stimulation of the cAMP-dependent protein kinase A pathway, and are finally associated with reduced cardiac function in those patients [13]. The pathogenic potential of β1-AR-specific autoantibodies was affirmed by recent studies in which recipient rodents developed DCM after passive transfer of β1-AR-specific antisera [17]. Jane-wit et al. [18] also reported that sustained agonism by β1-AR autoantibodies elicited caspase-3 activation, cardiomyocyte apoptosis, and DCM in vivo.

An extremely high incidence of anti-β1-AR autoantibodies is also reported in end-stage DCM patients who require mechanical cardiac support [12]. In selective patients in whom cardiac function can be normalized by mechanical cardiac support, a gradual disappearance of autoantibodies accompanies the recovery. Other clinical evidence have documented that the presence of these autoantibodies is closely related to serious ventricular arrhythmias [19,20] and predicts increased cardiovascular mortality risk in DCM.
We screened for anti-β1-AR autoantibodies against the second extracellular loop of human β1-AR in 52 patients with chronic heart failure, and found that the mean values of autoantibodies in those patients were significantly higher than those in normal control subjects (Fig. 1) [22]. Furthermore, during a follow-up of 3 years, patients with cardiac events had high anti-β1-AR autoantibody titers compared with patients without cardiac events. Thus, measurements of the β1-AR autoantibodies are important and useful for the management of chronic heart failure patients.

**IMMUNOADSORPTION THERAPY**

Removal of β1-AR autoantibodies with immunoadsorption (IA) is achieved by passing a patient’s plasma over columns that remove immunoglobulins (Fig. 2). This IA for patients with DCM was first reported in an uncontrolled pilot study by Wallukat et al. [23], who showed that this technique efficiently removed circulating antibodies directed against the β1-AR. They also observed an improvement in NYHA functional class in those patients. That study was followed by other pilot studies that reported an improvement in short- and long-term hemodynamic effects in patients with heart failure, who were refractory to conventional medical therapy [24-26]. Dorffel et al. [24] performed IA on nine patients with DCM, left ventricular ejection fraction (LVEF) <25% on 5 consecutive days. During therapy, hemodynamic parameters were monitored with a Swan-Ganz thermodilution catheter. In those patients, a significant increase in cardiac output (from 3.7±0.8 to 5.5±1.8 L/min; p<0.01) and a significant decrease in mean arterial pressure and mean pulmonary arterial pressure was noted. Felix et al. [25] randomized 25 patients with DCM, LVEF<30% with evidence of β1-AR autoantibody to IA therapy vs. conventional therapy. The treatment group underwent monthly IA followed by immunoglobulin substitution for 3 months. IA therapy led to a significant decrease in β1-AR autoantibody levels. The increase in LVEF and improvement of NYHA class were significantly greater in the treatment group compared with those in the control group. Muller et al. [26] evaluated 34 patients with DCM with NYHA class II-IV, LVEF<29%, and evidence of elevated levels of β1-AR autoantibodies. The active treatment group of 17 patients underwent IA on 5 consecutive days. At 1 year, the treatment group experienced a significant increase in LVEF (0.22 to 0.38, p=0.0001) and improvement in NYHA class compared with no significant changes in LVEF in the control group. Staudt et al. [27] studied the effect of IA on plasma nt-BNP and nt-ANP levels in 15 patients demonstrating severe heart failure (LVEF<35%) due to DCM. Four courses of IA therapy were performed at monthly intervals until month 3. Three months after IA, patients demonstrated significant improvement in LVEF, reduction in left ventricular dimension and plasma nt-BNP levels. Those single-center, case-control studies suggested that IA therapy could improve NYHA class and LVEF in subjects with chronic DCM and heart failure.
was associated with a significant improvement in the quality of life for up to 6 months after treatment. Global wall motion, as assessed by two-dimensional strain echocardiography, also showed a tendency towards improvement at 6 months.

Although IA is a new therapeutic option for patients with DCM, the mechanism of left ventricular functional benefit from IA is not known. IgG adsorption removes not only anti-β1-AR autoantibodies but also all other potentially pathogenic autoantibodies affecting the heart in this class of immunoglobulins. Mobini et al. [35] has reported that the effect of hemodynamic improvement during IA was similar among patients positive and negative for β1-AR autoantibodies. Their results suggest that the beneficial effects of IA are not directly associated with the selective elimination of β1-AR autoantibodies [36]. Schimke et al. [37] reported that a decrease in oxidative stress may be functionally important. In their study, three measures of oxidative stress, thiobarbituric acid-reactive substances, lipid peroxides, and antioxidized low density lipoprotein antibodies decreased significantly one year after selective IA of anti-β1-AR-autoantibodies with improvement of cardiac performance.

FUTURE DIRECTIONS

According to previous reports, the following questions remain to be resolved [38]: First, it will be important to identify the subsets of patients with DCM that will benefit the most from IA therapy, or determine whether patients with elevated levels of circulating autoantibodies (e.g., anti-β1-AR autoantibodies) should be studied. Second, the mechanism(s) underlying the action of IA have not yet been identified. Although studies have demonstrated decreases in circulating autoantibodies, it is not at all clear that a cause-and-effect relationship has been established. Third, the optimal strategy for IA has yet to be determined. Different investigators use different protocols and different immunoadsorbent devices. Moreover, the use of IVIG replacement in some of the IA protocols may improve the clinical status of patients with DCM [39], rather than neutralization of β1-AR autoantibodies. Finally, it is not clear from existing studies whether IA alone, which would be expected to modulate humoral immunity, will be sufficient over the long term, or whether it may be necessary to incorporate strategies that lead to suppression of cellular-mediated immunity as well. It is time to consider performing randomized clinical trials with IA in order to answer these questions.

CONCLUSION

Measurements of anti-β1-AR autoantibodies may be helpful for the monitoring of clinical status in patients with DCM. IA therapy to eliminate autoantibodies is a new and promising therapeutic option for those patients. However, further studies are necessary to elucidate the specific antigens of cardiac autoantibodies as well as cellular mechanisms responsible for the observed functional effects.

REFERENCES

[1] Taylor D, Edwards L, Boucek M, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult heart transplantation report. J Heart Lung Transplant 2006; 25: 869-79.

[2] Maisch B, Ristic AD, Hufnagel G, et al. Pathophysiology of viral myocarditis: the role of humoral immune response. Cardiovasc Pathol 2002; 11: 112-22.

[3] Schulze K, Becker BF, Schauer R, et al. Antibodies to ADP-ATP carrier-antigen in myocarditis and dilated cardiomyopathy - impact cardiac function. Circulation 1990; 81: 959-69.

[4] Caforio AL, Grazzini M, Mann JM, et al. Identification of alpha- and beta-cardiac myosin heavy chain isoforms as major autoantigens in dilated cardiomyopathy. Circulation 1992; 85: 1734-42.

[5] Limas CJ, Goldenberg IF, Limas C. Autoantibodies against beta-adrenergoreceptors in human idiopathic dilated cardiomyopathy. Circ Res 1989; 64: 97-103.

[6] Magnusson Y, Wallukat G, Waasten F, et al. Autoimmunity in idiopathic dilated cardiomyopathy. Circulation 1989; 80: 1528-34.

[7] Fu LX, Magnusson Y, Bergh CH, et al. Localization of a functional autocrine epitope on the muscarinic acetylcholine receptor-2 in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1993; 91: 1964-8.

[8] Okazaki T, Honjo T. Pathogenic roles of cardiac autoantibodies in dilated cardiomyopathy. Trends Mol Med 2005; 11: 322-6.

[9] Matsui S, Fu ML, Katsuda S, et al. Peptides derived from cardiovascular G-protein-coupled receptors induce morphological cardiomyopathic changes in immunized rabbits. J Mol Cell Cardiol 1997; 29: 641-55.

[10] Iwata M, Yoshikawa T, Baba A, et al. Autoimmunity against the second extracellular loop of beta-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo. Circ Res 2001; 88: 578-86.

[11] Jahns R, Boivin V, Hein L, et al. Direct evidence for a beta-adrenergic receptor-directed autoimmune attack as a cause of idiopathic dilated cardiomyopathy. Circulation 2004; 113: 1734-42.

[12] Muller J, Wallukat G, Weng YG, et al. Weaning from mechanical cardiac support in patients with idiopathic dilated cardiomyopathy. Circulation 1997; 96: 542-9.

[13] Jahns R, Boivin V, Siegmund C, et al. Autoantibodies activating human β1-adrenergic receptors are associated with reduced cardiac function in chronic heart failure. Circulation 1999; 99: 649-54.

[14] Christ T, Wettwer E, Dobre D, et al. Autoantibodies against the beta-adrenergoreceptor from patients with dilated cardiomyopathy prolong action potential duration and enhance contractility in isolated cardiomyocytes. J Mol Cell Cardiol 2001; 33: 1515-25.

[15] Wallukat G, Welleberger A. Effect of the serum gamma globulin fraction of patients with allergic asthma and dilated cardiomyopathy on chronotropic β-adrenergic receptor function in cultured neonatal rat heart myocytes. Biomed Biochim Acta 1987; 46: 634-9.

[16] Magnusson Y, Marullo S, Hoyer S, et al. Mapping of a functional autoimmune epitope on the β1 adrenergic receptor in patients with idiopathic dilated cardiomyopathy. J Clin Invest 1990; 86: 1658-63.

[17] Matsui S, Fu M, Hayase M, et al. Transfer of rabbit autoimmune cardiomyopathy into severe combined immunodeficiency mice. J Cardiovasc Pharmacol 2003; 42: S99-S103.

[18] Jane-wit D, Altuntas CZ, Johnson JM, et al. β1-adrenergic receptor autoantibodies mediate dilated cardiomyopathy by agonistically inducing cardiomyocyte apoptosis. Circulation 2007; 116: 399-410.

[19] Fukuda Y, Miyoshi S, Tanimoto K, et al. Autoimmunity against the second extracellular loop of beta-adrenergic receptors induces early afterdepolarization and decreases in K-channel density in rabbits. J Am Coll Cardiol 2004; 43: 1090-100.

[20] Iwata M, Yoshikawa T, Baba A, et al. Autoantibodies against the second extracellular loop of beta-adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 2001; 37: 418-24.

[21] Stork S, Boivin V, Horf R, et al. Stimulation autoantibodies directed against the cardiac beta-adrenergic receptor predict increased mortality in idiopathic cardiomyopathy. Am Heart J 2006; 152: 697-704.

[22] Aso S, Yazaki Y, Kasai H, et al. Association between anti-beta-adrenergic receptor autoantibodies and myocardial sympathetic nervous activity assessed with iodine-123 metaiodobenzylguanidine scintigraphy in cases of chronic heart failure. Int J Cardiol 2008; Epub a head of print.
[23] Wallukat G, Reinke P, Dorffel WV, et al. Removal of autoantibodies in dilated cardiomyopathy by immunoadsorption. Int J Cardiol 1996; 54:191-5.

[24] Dorffel W, Felix S, Wallukat G, et al. Short-term hemodynamic effects of immunoadsorption in dilated cardiomyopathy. Circulation 1997; 95: 1994-7.

[25] Felix SB, Staudt A, Dorffel W, et al. Hemodynamic effects of immunoadsorption and subsequent immunoglobulin substitution in dilated cardiomyopathy: three month results from a randomized study. J Am Coll Cardiol 2000; 35: 1590-8.

[26] Muller J, Wallukat G, Dandel M, et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000; 101: 385-91.

[27] Staudt A, Staudt Y, Hummel A, et al. Effects of Immunoadsorption on the n-t-BNP and n-t-ANP plasma levels of patients suffering from dilated cardiomyopathy. Ther Apher Dial 2006; 10: 42-8.

[28] Wallukat G, Muller J, Hetzer R. Specific removal of β1-adrenergic autoantibodies from patients with idiopathic dilated cardiomyopathy (letter). N Engl J Med 2002; 347: 1806.

[29] Staudt A, Schaper F, Stangl V, et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001; 103: 2681-6.

[30] Staudt A, Bohm M, Knebel F, et al. Potential role of autoantibodies belonging to the immunoglobulin G3 subclass in cardiac dysfunction among patients with dilated cardiomyopathy. Circulation 2002; 106: 2448-55.

[31] Staudt A, Dorff M, Staudt Y, et al. Role of immunoglobulin G3 subclass in dilated cardiomyopathy: results from protein A immunoadsorption. Am Heart J 2005; 150: 729-736.

[32] Cooper LT, Belohlavek M, Korinek J, et al. A pilot study to assess the use of protein A immunoadsorption for chronic dilated cardiomyopathy. J Clin Apheresis 2007; 22: 210-4.

[33] McNamara DM, Holubkov R, Starling RC, et al. Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy. Circulation 2001; 103: 2254-9.

[34] Schmaldienst S, Mullner M, Goldammer A, et al. Intravenous immunoglobulin application following immunoadsorption: benefit or risk in patients with autoimmune diseases? Rheumatology (Oxford) 2001; 40: 513-21.

[35] Mobini R, Staudt A, Felix SB, et al. Hemodynamic improvement and removal of autoantibodies against β1-adrenergic receptor by immunoadsorption therapy in dilated cardiomyopathy. J Autoimmun 2003; 20: 345-50.

[36] Felix SB, Staudt A, Landsberger M, et al. Removal of cardiodepressant antibodies in dilated cardiomyopathy by immunoadsorption. J Am Coll Cardiol 2002; 39: 646-52.

[37] Schimke I, Muller JJ, Priem F, et al. Decreased oxidative stress in patients with idiopathic dilated cardiomyopathy one year after immunoglobulin adsorption. J Am Coll Cardiol 2002; 38: 178-83.

[38] Mann DL. Autoimmunity, immunoglobulin adsorption and dilated cardiomyopathy: has the time come for randomized clinical trials? J Am Coll Cardiol 2001; 37: 184-6.

[39] Larsson L, Mobini R, Aukrust P, et al. Beneficial effect on cardiac function by intravenous immunoglobulin treatment in patients with dilated cardiomyopathy is not due to neutralization of anti-receptor autoantibody. Autoimmunity 2004; 37: 489-93.